Leukemia Clinical Trials in Nashville

Showing 241-260 of 814 trials

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06040541

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)+1 more

Revolution Medicines, Inc.604 participantsStarted Sep 2023

Sacramento, California, United States • New Haven, Connecticut, United States • Sarasota, Florida, United States +14 more locations

ACTIVE_NOT_RECRUITINGPHASE3< 1 mile

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

NCT02475681

This Primary objective is evaluating the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib in combination with obinutuzumab (Arm B) for the treatment of previously untreated chronic lymphocytic leukemia (CLL). Secondary objectives: 1) To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm A) versus acalabrutinib monotherapy (Arm C) based on IRC assessment of PFS per IWCLL 2008 criteria. 2)To compare obinutuzumab plus chlorambucil (Arm A) versus acalabrutinib plus obinutuzumab (Arm B) and obinutuzumab plus chlorambucil (Arm A) versus acalabrutinib monotherapy (Arm C) in terms of: IRC-assessed objective response rate (ORR); Tine to next treatment (TTNT); Overall Survival (OS)

Chronic Lymphocytic Leukemia

Acerta Pharma BV535 participantsStarted Jun 2015

Goodyear, Arizona, United States • Phoenix, Arizona, United States • Anaheim, California, United States +152 more locations

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

Leukemia Trials in Other Cities

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Expanded Access of Sotorasib

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

Transorb™ Self-Gripping Resorbable Mesh in High-risk Subjects Undergoing Open Repair of Ventral Hernia

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

A Long-term Follow-up Study of Patients Who Received VOR33

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder

Other Conditions in Nashville